{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:37:52Z","timestamp":1790059072352,"version":"4.0.1"},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T00:00:00Z","timestamp":1413417600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0110188","type":"journal-article","created":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T21:13:46Z","timestamp":1413839626000},"page":"e110188","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effects of Cytochrome P450 2C19 and Paraoxonase 1 Polymorphisms on Antiplatelet Response to Clopidogrel Therapy in Patients with Coronary Artery Disease"],"prefix":"10.1371","volume":"9","author":[{"given":"Damrus","family":"Tresukosol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhoom","family":"Suktitipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saowalak","family":"Hunnangkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruttakarn","family":"Kamkaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiphon","family":"Poldee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boonrat","family":"Tassaneetrithep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atip","family":"Likidlilid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,10,16]]},"reference":[{"key":"ref1","first-page":"21","article-title":"Costs of payment in Thai acute coronary syndrome patients","volume":"90","author":"W Moleerergpoom","year":"2007","journal-title":"J Med Assoc Thai"},{"key":"ref2","article-title":"Anti-platelet therapy for Acute Coronary Syndrome: A review of currently available agents and what the future holds","author":"FA Syed","year":"2011","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"ref3","first-page":"216","article-title":"ACC\/AHA\/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (ACC\/AHA\/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)","volume":"47","author":"SC Smith Jr","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ncpcardio0602","article-title":"Drug insight: Clopidogrel nonresponsiveness","volume":"3","author":"PA Gurbel","year":"2006","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"PA Gurbel","year":"2003","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"DJ Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2796.2002.01027.x","article-title":"Individual variations of platelet inhibition after loading doses of clopidogrel","volume":"252","author":"P Jaremo","year":"2002","journal-title":"J Intern Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.2337\/diabetes.54.8.2430","article-title":"Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment","volume":"54","author":"DJ Angiolillo","year":"2005","journal-title":"Diabetes"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1055\/s-0037-1613462","article-title":"Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement","volume":"89","author":"I Muller","year":"2003","journal-title":"Thromb Haemost"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.amjcard.2003.10.042","article-title":"Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization","volume":"93","author":"JE Mobley","year":"2004","journal-title":"Am J Cardiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"S Matetzky","year":"2004","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2004.07.007","article-title":"Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting","volume":"115","author":"DJ Angiolillo","year":"2005","journal-title":"Thromb Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite","volume":"38","author":"M Kazui","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"JS Hulot","year":"2006","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel","volume":"5","author":"JT Brandt","year":"2007","journal-title":"J Thromb Haemost"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1538-7836.2008.03050.x","article-title":"The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects","volume":"6","author":"K Umemura","year":"2008","journal-title":"J Thromb Haemost"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"T Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"D Sibbing","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"L Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","article-title":"Paraoxonase-1 is a major determinant of clopidogrel efficacy","volume":"17","author":"HJ Bouman","year":"2011","journal-title":"Nat Med"},{"key":"ref21","first-page":"13","article-title":"Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response","volume":"4","author":"RP Kreutz","year":"2012","journal-title":"Clin Pharmacol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/eurheartj\/ehr155","article-title":"No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting","volume":"32","author":"D Sibbing","year":"2011","journal-title":"Eur Heart J"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1161\/CIRCGENETICS.111.961417","article-title":"Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events","volume":"5","author":"G Pare","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.clinbiochem.2008.09.120","article-title":"The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment","volume":"42","author":"J Marsillach","year":"2009","journal-title":"Clin Biochem"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.299.11.1265","article-title":"Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk","volume":"299","author":"T Bhattacharyya","year":"2008","journal-title":"JAMA"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0140-6736(05)61755-2","article-title":"Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation","volume":"349","author":"MI Mackness","year":"1997","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2156-5-17","article-title":"The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women&apos;s Heart and Health cohort study and a meta-analysis","volume":"5","author":"DA Lawlor","year":"2004","journal-title":"BMC Genet"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jacc.2009.05.061","article-title":"Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention","volume":"54","author":"JJ Regieli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/AC.65.6.2059866","article-title":"Paraoxonase 1 polymorphisms as the risk factor of coronary heart disease in a Thai population","volume":"65","author":"A Likidlilid","year":"2010","journal-title":"Acta Cardiol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0021-9150(98)00179-8","article-title":"The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan","volume":"141","author":"YL Ko","year":"1998","journal-title":"Atherosclerosis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0021-9150(99)00340-8","article-title":"Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases","volume":"149","author":"Y Imai","year":"2000","journal-title":"Atherosclerosis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0009-9120(02)00295-3","article-title":"Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease","volume":"35","author":"N Ferre","year":"2002","journal-title":"Clin Biochem"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"JA Goldstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1160\/TH07-07-0478","article-title":"Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment","volume":"99","author":"D Sibbing","year":"2008","journal-title":"Thromb Haemost"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/1076029611429122","article-title":"Description of response to aspirin and clopidogrel in outpatients with coronary artery disease using multiple electrode impedance aggregometry","volume":"18","author":"GT Gerotziafas","year":"2012","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","article-title":"The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans","volume":"269","author":"SM de Morais","year":"1994","journal-title":"J Biol Chem"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","article-title":"Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese","volume":"46","author":"SM De Morais","year":"1994","journal-title":"Mol Pharmacol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.exger.2004.03.017","article-title":"Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians","volume":"39","author":"S Campo","year":"2004","journal-title":"Exp Gerontol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1093\/hmg\/11.20.2463","article-title":"Epistasis: what it means, what it doesn&apos;t mean, and statistical methods to detect it in humans","volume":"11","author":"HJ Cordell","year":"2002","journal-title":"Hum Mol Genet"},{"key":"ref40","article-title":"scrime: Analysis of High-Dimensional Categorical Data such as SNP Data","author":"H Schwender","year":"2013"},{"key":"ref41","unstructured":"R Core Team (2013) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.R-project.org\" xlink:type=\"simple\">http:\/\/www.R-project.org<\/ext-link>."},{"key":"ref42","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"AR Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/j.1538-7836.2010.03921.x","article-title":"Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy","volume":"8","author":"D Sibbing","year":"2010","journal-title":"J Thromb Haemost"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"JL Mega","year":"2009","journal-title":"Circulation"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"JL Mega","year":"2010","journal-title":"Lancet"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"JL Mega","year":"2010","journal-title":"JAMA"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement","volume":"55","author":"W Hochholzer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G&gt;A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"D Trenk","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"D Sibbing","year":"2009","journal-title":"Eur Heart J"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"JP Collet","year":"2009","journal-title":"Lancet"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"JL Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/eurheartj\/ehq321","article-title":"CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study","volume":"31","author":"AM Harmsze","year":"2010","journal-title":"Eur Heart J"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/clpt.2011.193","article-title":"Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction","volume":"90","author":"T Simon","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1161\/CIRCGENETICS.111.960112","article-title":"Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement","volume":"4","author":"D Trenk","year":"2011","journal-title":"Circ Cardiovasc Genet"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1111\/j.1538-7836.2011.04409.x","article-title":"Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study","volume":"9","author":"P Fontana","year":"2011","journal-title":"J Thromb Haemost"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2217\/pgs.11.73","article-title":"Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention","volume":"12","author":"O Rideg","year":"2011","journal-title":"Pharmacogenomics"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/clpt.2011.194","article-title":"Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response","volume":"90","author":"JP Lewis","year":"2011","journal-title":"Clin Pharmacol Ther"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0110188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T07:30:19Z","timestamp":1746430219000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0110188"}},"subtitle":[],"editor":[{"given":"Carmine","family":"Pizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,16]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0110188","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,16]]}}}